19 Nov 2021
byAudrey Abella
The monoclonal antibody lanadelumab demonstrated long-term efficacy for patients with hereditary angioedema (HAE) who had received prophylactic lanadelumab for ≥12 months, according to findings from the post hoc analysis of the phase III HELP OLE* study presented at ACAAI 2021.